about
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.
P50
description
researcher ORCID ID = 0000-0002-5793-2322
@en
wetenschapper
@nl
name
Dmitriy Rekalov
@ast
Dmitriy Rekalov
@en
Dmitriy Rekalov
@es
Dmitriy Rekalov
@nl
type
label
Dmitriy Rekalov
@ast
Dmitriy Rekalov
@en
Dmitriy Rekalov
@es
Dmitriy Rekalov
@nl
prefLabel
Dmitriy Rekalov
@ast
Dmitriy Rekalov
@en
Dmitriy Rekalov
@es
Dmitriy Rekalov
@nl
P106
P1153
55479828200
56033627000
P31
P496
0000-0002-5793-2322